Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury’s previous verdict. The jury determined the Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.
